MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Edaravone

CAS No. : 89-25-8

MCE 站：Edaravone

产品活性：Edaravone 是一种新颖的，有效的自由基清除剂，能够抑制大鼠与 MMP-9 有关的脑出血。

研究领域：Metabolic Enzyme/Protease  |  Apoptosis

作用靶点：MMP  |  Apoptosis

In Vitro: Edaravone performs both preventative and therapeutic effects against toxicity of glutamate. Pretreatment of edaravone reduces the toxicity of glutamate towards SGNs. Edaravone reduces apoptosis and necrosis caused by glutamate. Pretreatment of edaravone (500 μM) reverses these changes to approximately normal levels. The protective effect of edaravone on SGNs against glutamate-induced apoptosis is associated with PI3K/Akt pathway and Bcl-2 protein family.

In Vivo: Edaravone exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Edaravone provides the desirable features of NOS: it increases eNOS (beneficial NOS for rescuing ischemic stroke) and decreases nNOS and iNOS (detrimental NOS). Post-reperfusion brain edema and hemorrhagic events induced by thrombolytic therapy may be reduced by edaravone pretreatment. Edaravone significantly decreases infarct volume, with the average infarct volume in the edaravone-treated rats (227.6 mm³) being significantly lower than that in the control rats (264.0 mm³). Edaravone treatment also decreases the postischemic hemorrhage volumes (53.4 mm³ in edaravone-treated rats vs 176.4 mm³ in controls). In addition, the ratio of hemorrhage volume to infarct volume is lower in the edaravone-treated rats (23.5%) than in the untreated rats (63.2%). In edaravone (20 mg/kg)-treated rats, astrocyte activity (glial fibrillary acidic protein) and apoptotic cells (caspase-3) are decreased on the corpus callosum, germinal matrix, and cerebral cortex.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  CNS-Penetrant Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Anti-COVID-19 Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Neuroprotective Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  Verteporfin  |  Doxycycline (hyclate)  |  Decitabine  |  Actinomycin D  |  Temozolomide  |  BAY 11-7082  |  Etoposide  |  Mitomycin C  |  CCCP  |  DAPT  |  Rote  |  Etomoxir  |  Stattic  |  Docetaxel

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。